Breakthrough Device Designation in 2026: What the Data Actually Shows

Breakthrough Device Designation has become one of the most sought-after signals in medtech — sponsors cite it in investor decks, press releases, and partnership pitches. But the program’s actual mechanics, and its real conversion rate from designation to marketing authorization, are less widely understood than the label itself. FDA’s own data, updated through the first half of 2026, tells a more nuanced story than the headline number suggests.

What the Program Actually Grants

Breakthrough Device Designation, established by Section 3051 of the 21st Century Cures Act (codified as Section 515B of the FD&C Act), is not itself a marketing authorization. It’s a designation that changes how FDA interacts with a sponsor during development — more frequent and structured engagement through the Q-Submission process, flexible clinical study design discussions, and priority review once a marketing submission is filed. The underlying pathway — 510(k), De Novo, or PMA — still applies; Breakthrough status doesn’t substitute for it.

The program absorbed the earlier Expedited Access Pathway (EAP), established in 2014, and FDA counts EAP-designated devices within current Breakthrough Devices Program statistics.

The Numbers Through 2026

As of March 31, 2026, CDRH and CBER had granted 1,284 Breakthrough Device designations since the program’s inception — 1,264 through CDRH and 20 through CBER. Of those, 198 devices had gone on to receive marketing authorization (193 CDRH devices and five CBER devices).

That ratio — roughly 15% of all designated devices reaching marketing authorization — is the number sponsors and investors should be paying closest attention to, and it’s frequently absent from how the designation gets discussed publicly. It doesn’t mean 85% of designated devices have failed; many are still actively in development, since designation can be granted years before a marketing submission is filed. But it does mean designation is a leading indicator of FDA engagement, not a predictor of near-term market entry — a distinction that matters for regulatory strategy, capital planning, and partner due diligence alike.

Industry trackers have described the resulting distribution — a growing pool of designated-but-not-yet-authorized devices — as a “valley of death” between designation and market. That framing likely overstates outright attrition rather than reflecting the simple reality that de novo and PMA-track devices in particular can spend years in development after designation. Still, the width of that gap is real and growing as annual designation volume outpaces annual authorizations.

Where Designations Are Concentrated

FDA’s program data is broken out by clinical panel and fiscal year, and recent updates show a clear compositional shift: diagnostics has become the fastest-growing category of new designations, even as overall new-designation volume has held roughly steady year over year. This tracks with the broader growth in AI-enabled diagnostic and monitoring software, where algorithmic tools targeting earlier or more accurate detection of serious conditions align closely with the program’s eligibility criteria — devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

AI-powered devices now represent a substantial and growing share of the more than 1,200 devices designated since the program’s 2016 launch, and FDA’s evaluation approach appears to be evolving alongside that shift — reporting suggests the agency has increasingly favored designations for devices addressing multiple clinical problems simultaneously, rather than single-metric diagnostic improvements alone.

The Alternative Sponsors Overlook: STeP

For devices that don’t meet Breakthrough’s “life-threatening or irreversibly debilitating” threshold but still offer meaningful safety improvements, FDA’s Safer Technologies Program (STeP) offers a parallel expedited pathway with a lower eligibility bar. Sponsors developing devices with genuine safety benefits — but treating conditions that don’t rise to Breakthrough’s severity criteria — should evaluate STeP rather than assuming Breakthrough is the only expedited option or, worse, forcing a Breakthrough application that doesn’t fit the criteria and risks unnecessary review delay.

What Sponsors Should Take From This

Designation timing matters more than designation itself. Because Breakthrough status can be requested early — well before pivotal clinical data exists — sponsors should treat the application as a development-stage strategic decision, not a late-stage marketing move. The enhanced FDA interaction is most valuable when there’s still time to shape the evidence generation plan around it.

Don’t treat the conversion rate as a red flag. A roughly 15% cumulative designation-to-authorization rate reflects the pipeline nature of the program more than it reflects program failure — but sponsors and their investors should model realistic time-to-market rather than assuming designation compresses the timeline as dramatically as its marketing reputation suggests.

Evaluate STeP honestly before defaulting to Breakthrough. Applying for the wrong expedited program, or applying prematurely, consumes review bandwidth without the intended acceleration benefit.

Track panel-level trends when benchmarking competitors. Because designation data is public and broken out by clinical panel, it’s a genuinely useful competitive intelligence source — sponsors can see where FDA attention and designation density is concentrated within their own category, ahead of a submission.

The Breakthrough Devices Program remains one of FDA’s most effective tools for accelerating genuinely novel technology to patients. But its value is in the development-stage relationship it creates with the review division — not in the designation as a standalone credential. Sponsors that plan around that distinction get more out of the program than those chasing the label alone.

This article reflects FDA program data published through March 2026 and is intended for general regulatory and educational purposes. It does not constitute regulatory or legal advice for a specific device or submission.